Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On July 19, 2023, we reported on a study published in the Journal of the American Heart Association that found troubling disparities between men and women in emergency service routing for acute ishemic stroke (AIS).
The study
For the cross-sectional study, the research team identified consecutive patients presenting with large vessel occlusion AIS from a prospectively-collected multihospital registry for the greater Houston area from January 2019 to June 2020. Of the 10 stroke centers included, 6 are primary stroke centers (PSCs) and 4 are comprehensive stroke centers.
The findings
The team found that women with LVO AIS were more likely to be older than men (73 vs 65 years) and to be sicker as determined by National Institutes of Health Stroke Scale score. Despite the more severe presentation, however, multivariable analysis confirmed that women were less likely to be routed to a comprehensive stroke center than men, a disparity that persisted regardless of the comparable promixmity to a stroke center.
Conclusion
The authors conclude, in part, that "...elderly women are more likely to live alone and experience social isolation, which can result in delayed recognition of stroke symptoms and subsequent delays in seeking medical attention. Therefore, appropriate triage and prehospital routing can be even more critical for women."
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.
Cheryl Cox Kinney, MD, explains when night sweats warrant further evaluation, including red flags, persistent symptoms, and potential nonmenopausal causes.
TMS 2026: Menopause was coded in just 7.8% of midlife outpatient visits. Arina Chesnokova, MD, MPH, discusses diagnosis gaps, prescribing risks, and solutions for primary care.
TMS 2026: Nearly 67% of US women receiving elinzanetant achieved at least a 50% reduction in menopausal VMS frequency by week 12 in pooled phase 3 trial data.
TMS 2026: Only 21.7% of women initiated menopause hormone therapy, with significant racial disparities and low treatment persistence, a new study finds.
TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.